Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Large Randomised Placebo Controlled Trial Among Trauma Patients With, or at Risk of, Significant Haemorrhage, of the Effects of Antifibrinolytic Treatment on Death and Transfusion Requirement
Brief Summary: CRASH 2 is a large pragmatic randomised placebo controlled trial of the effects of the early administration of the antifibrinolytic agent tranexamic acid on death, vascular events and transfusion requirements. Adults with trauma who are within 8 hours of injury and have either significant haemorrhage, or who are considered to be at risk of significant haemorrhage, are eligible if the responsible doctor is for any reason substantially uncertain whether or not to use an antifibrinolytic agent. Numbered drug or placebo packs will be available in each participating emergency department. Randomisation will involve calling a 24-hour freecall randomisation service. The call should last only a minute or two and at the end of it the randomisation service will specify which numbered treatment pack to use. For hospitals where telephone randomisation is not feasible, randomisation will be by taking the next consecutively numbered treatment pack. No extra tests are required but a short form must be completed one month later or on discharge or on death (whichever occurs first).


Options:
A: Arm Label: tranexamic acid 1 g (TA1); Type: EXPERIMENTAL; Interventions: Drug: tranexamic acid 1 g (TA1) | Arm Label: tranexamic acid 0.5 g (TA1/2); Type: EXPERIMENTAL; Interventions: Drug: tranexamic acid 0.5 g (TA1/2) | Arm Label: Saline Solution (TA0); Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline Solution (TA0) | Arm Label: NH; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: tranexamic acid 1 g (TA1); Assigned to Arm(s): tranexamic acid 1 g (TA1) | Intervention Type: DRUG; Name: tranexamic acid 0.5 g (TA1/2); Assigned to Arm(s): tranexamic acid 0.5 g (TA1/2) | Intervention Type: DRUG; Name: Saline Solution (TA0); Assigned to Arm(s): Saline Solution (TA0)
B: Arm Label: Tranexamic acid group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic Acid, Procedure: Cesarean section | Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Cesarean section | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Tranexamic acid group | Intervention Type: PROCEDURE; Name: Cesarean section; Assigned to Arm(s): Control group, Tranexamic acid group
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sodium Chloride 0.9% | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sodium Chloride 0.9%; Assigned to Arm(s): 2
D: Arm Label: Tranexamic Acid (TXA); Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic Acid | Arm Label: Placebo (0.9% normal saline); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (Saline) | Arm Label: Hypotension-avoidance strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Perioperative hypotension-avoidance strategy | Arm Label: Perioperative hypertension-avoidance strategy; Type: PLACEBO_COMPARATOR; Interventions: Other: Perioperative hypertension-avoidance strategy | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Tranexamic Acid (TXA) | Intervention Type: DRUG; Name: Placebo (Saline); Assigned to Arm(s): Placebo (0.9% normal saline) | Intervention Type: OTHER; Name: Perioperative hypotension-avoidance strategy; Assigned to Arm(s): Hypotension-avoidance strategy | Intervention Type: OTHER; Name: Perioperative hypertension-avoidance strategy; Assigned to Arm(s): Perioperative hypertension-avoidance strategy

Answer: C